CD4 and carcinoma: The low expression of PD-L1 in carcinomas with p53 mutations, along with high levels of Tregs and/or decreased levels of CD4+ and CD8+ cells in p53-GOF oral lesions, suggest that p53-GOF promotes an immune microenvironment that may compromise the efficacy of immune checkpoint inhibitors.